I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
SHANGHAI, China and GAITHERSBURG, Md., March 11, 2021 (GLOBE NEWSWIRE) -- I-Mab (the “Company”) (NASDAQ: IMAB), a clinical stage biopharmaceutical...